|ASN002 is an orally bioavailable dual spleen tyrosine kinase (SYK)/pan Janus kinase (JAK) inhibitor that is being developed by Asana BioSciences. It is being evaluated for clinical efficacy in inflammatory and oncology settings. The chemical structure shown here matches the IUPAC name and CAS number submitted to the WHO for the INN gusacitinib. Not to be confused with Ascend Biopharmaceuticals immuno-oncology lead ASN-002, which is an engineered virus that expresses IFN-γ.
ASN002 is one of the chemical structures (example 189) claimed in Asana Biosciences' patent WO2013028818A1 .